Anacor Pharmaceuticals

Anacor Pharmaceuticals is a biopharmaceutical company that specializes in discovering, developing, and commercializing small-molecule therapeutics based on its boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis of the toenails. Its lead candidate, crisaborole topical ointment, is currently in Phase III clinical trials aimed at addressing mild-to-moderate atopic dermatitis and psoriasis. Additionally, Anacor is developing AN3365, an antibiotic for infections caused by Gram-negative bacteria. The company has established collaboration agreements with various organizations to explore new treatments for diseases such as African trypanosomiasis, tuberculosis, and Chagas disease. Anacor Pharmaceuticals, which was incorporated in 2000 and is headquartered in Palo Alto, California, previously operated under the name AnaMax, Inc. It has been a subsidiary of Pfizer since June 2016.